On Wednesday, the Technical Advisory Group of WHO has recommended the Emergency Use Listing status for Bharat Biotech’s Covaxin – a decision that will ease international travel and the export of the indigenous vaccine. Last week, WHO’s panel had sought additional clarifications from the Hyderabad-based pharma firm. Covaxin is a whole virion-inactivated vaccine against SARS-CoV2, developed in partnership with ICMR and NIV, Prune.
The World Health Organisation (WHO) on Wednesday approved India-made Covid-19 vaccine developed by Bharat Biotech. The WHO decision has been welcomed by the government.
Bharat Biotech: The vaccine developer, Bharat Biotech said that the countries can now expedite their regulatory approval processes to import & administer Covaxin.
In a statement, the company said: “With validation from WHO, countries can now expedite their regulatory approval processes to import & administer Covaxin. UNICEF, Pan-American Health Organization (PAHO), GAVI COVAX facility, will be able to procure Covaxin for distribution to countries worldwide.”
“Validation by WHO is a very significant step towards ensuring global access to India’s widely administered, safe, and efficacious Covaxin,” Bharat Biotech Chairman and Managing Director Krishna Ella was quoted as saying by news agency PTI.
As an organisation, Bharat Biotech has focused on maintaining stringent quality and safety standards that meet rigorous assessment, and scientific standards established by WHO, as a result, many of its vaccines have received WHO prequalification, he added.
